Xiuning Le, MD, PhD, discusses the confirmatory SOHO-02 trial needed to convert sevabertinib’s accelerated approval to full approval.

David R. Gandara, MD, discusses how EMPOWER-Lung 1’s findings in KRAS G12C-mutated disease should inform the design of combination trials.

Meletios A. Dimopoulos, MD, explored how anselamimab’s benefit in kappa light chain amyloidosis fits into the evolving role of anti-fibril therapy.

“Cardiovascular assessment should begin when the patient is being selected for treatment, not after the toxicity emerges,” said Faisal Mehmud, MD, MRCP.

Meletios A. Dimopoulos, MD, discussed where bispecific antibodies such as teclistamab may fit for patients with relapsed Waldenström macroglobulinemia.

Experts preview ASTRO 2026 presentations to watch, including those on SOFT Preop, PSMAgRT, radiosurgery for depression, and AI tools for patient safety.

David R. Gandara, MD, explains what makes KRAS G12C biologically distinct from other KRAS subtypes in NSCLC immunotherapy response.

Xiuning Le, MD, PhD, weighs sevabertinib against zongertinib and trastuzumab deruxtecan in HER2-mutant non–small cell lung cancer.